On June 30, Abivax S.A. rose 27.93% overnight, trading at 126.0 USD/share, with turnover of 1,356.0 USD.

On the news front, the company announced positive topline results from ABTECT Maintenance Part 2, a supplemental portion of its Phase 3 ulcerative colitis program evaluating obefazimod in patients who did not respond to induction or relapsed during the main maintenance trial. Among induction non-responders, 50 mg obefazimod achieved 37.2% clinical remission and 61.5% clinical response at Week 44. Among relapsed patients, re-treatment achieved clinical response and remission rates of 69.7% and 45.0%, respectively. Critically, no new safety signals emerged from Part 2.

The data is particularly significant given that the stock had previously plunged nearly 50% from approximately 130 USD to around 70 USD after multiple cancer cases were reported in the 50mg cohort. Some investors have since argued those cases were likely age-related rather than drug-related. With efficacy confirmed and safety concerns progressively digested, bullish sentiment has intensified, driving the stock to recover prior losses.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)